Novartis is announcing data from a new subgroup analysis of the Phase III NATALEE trial evaluating the efficacy and safety of Kisqali(R) (ribociclib) plus endocrine therapy (ET, a non-steroidal ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity.

China: A recent study published in the journal Gastroenterology has highlighted how alcohol consumption and genetic ...

The findings from the Women’s Health Initiative are in line with recent guidelines for the primary prevention of stroke.

A large US case-control study found that people diagnosed with herpes simplex virus type 1 (HSV-1) had a higher risk of ...

Certain women with major weight gain after their breast cancer diagnosis are at increased risk for breast cancer mortality, ...

This important study provides evidence for asymptomatic Bordetella pertussis carriage among mothers in a longitudinal cohort in Zambia, significantly advancing understanding of transmission dynamics.

Analysis of hospitalized patients with community-acquired pneumonia links azithromycin to lower mortality and more ...

Overall, women who received a COVID vaccine had a 19% greater risk of increase in menstrual cycle length as compared to ...

Indeed, the hazard ratio comparing febuxostat use ... There was no excess CV risk associated with febuxostat relative to allopurinol, even in those with preexisting CV disease.

A hazard ratio of 0.8 translates into a 20% risk ... to treat 1L-NSCLC pts with a drug that offers a ~22-23% relative risk reduction in death over the current gold-standard Keytruda, assuming ...